You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 290 No. 11, September 17, 2003 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (14)
 •Contact me when this article is cited
 Related Content
 •Related letters
 •Similar articles in JAMA
 Topic Collections
 •Quality of Care
 •Quality of Care, Other
 •Prognosis/ Outcomes
 •Drug Therapy
 •Medication Error
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati
What's this?

Retrospective Drug Utilization Review, Prescribing Errors, and Clinical Outcomes

Sean Hennessy, PharmD, PhD; Warren B. Bilker, PhD; Lan Zhou, PhD; Anita L. Weber, PhD; Colleen Brensinger, MS; Yanlin Wang, MS; Brian L. Strom, MD, MPH

JAMA. 2003;290:1494-1499.

Context  Retrospective drug utilization review is required of all state Medicaid programs and is performed by most private-sector prescription programs. However, it has not been shown to improve clinical outcomes or reduce the rate of potential prescribing errors, known as "exceptions."

Objective  To look for an effect of retrospective drug utilization review on the rate of exceptions and of clinical outcomes in patients with an exception.

Design, Setting, and Participants  Longitudinal ecologic study of the rate of exceptions, controlling for preintervention trends and calendar time; and a cohort study of all-cause and cause-specific hospitalizations in patients with an exception, controlling for potential individual-level confounders in 6 Medicaid programs using the same software in the mid-1990s.

Main Outcome Measures  The rate of exceptions was examined as a function of retrospective drug utilization review implementation. In addition, before-after comparisons were made of the incidence of all-cause and cause-specific hospitalization in patients with exceptions.

Results  We found no reduction in the rate of exceptions coincident with retrospective drug utilization review implementation (rate increase, 0.064 exceptions per 1000 prescriptions per month; 95% confidence interval [CI], -0.006 to 0.133). We also found no effect of retrospective drug utilization review on the incidence of all-cause hospitalization (odds ratio, 0.99; 95% CI, 0.98-1.00) or cause-specific hospitalization. These results persisted in multiple subgroup analyses. Study states intervened using physician alerts in between 1% and 25% of exceptions.

Conclusions  We were unable to identify an effect of retrospective drug utilization review on the rate of exceptions or on clinical outcomes. Given the lack of evidence for effectiveness, and suggestions from previous research of possible harm, policymakers should consider withdrawing the legislative mandate for retrospective drug utilization review.


Author Affiliations: Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, and Center for Education and Research in Therapeutics, University of Pennsylvania School of Medicine, Philadelphia.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati     What's this?

RELATED LETTERS

Evaluation of Drug Utilization Review Programs
Robert Berringer, Ellen Friedla, and Karen Rich
JAMA. 2004;291(2):184-185.
EXTRACT | FULL TEXT  

Evaluation of Drug Utilization Review Programs
Dale B. Christensen, William H. Campbell, Thomas R. Fulda, Mark C. Pugh, David H. Smith, Earlene E. Lipowski, Elgene W. Jacobs, Julie W. Kuhle, and Robert A. Crittenden
JAMA. 2004;291(2):185.
EXTRACT | FULL TEXT  

Evaluation of Drug Utilization Review Programs—Reply
Sean Hennessy, Warren B. Bilker, Anita L. Weber, Colleen Brensinger, and Brian L. Strom
JAMA. 2004;291(2):185-186.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Utility of Adding Retrospective Medication Profiling to Computerized Provider Order Entry in an Ambulatory Care Population
Glassman et al.
J. Am. Med. Inform. Assoc. 2007;14:424-431.
ABSTRACT | FULL TEXT  

Identification of Inappropriate Drug Prescribing by Computerized, Retrospective DUR Screening in Korea
Yeom et al.
The Annals of Pharmacotherapy 2005;39:1918-1923.
ABSTRACT | FULL TEXT  

From knowledge to practice in chronic cardiovascular disease: a long and winding road
Majumdar et al.
J Am Coll Cardiol 2004;43:1738-1742.
ABSTRACT | FULL TEXT  

Evaluation of Drug Utilization Review Programs
Christensen et al.
JAMA 2004;291:185-185.
FULL TEXT  

Evaluation of Drug Utilization Review Programs
Berringer et al.
JAMA 2004;291:184-185.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2003 American Medical Association. All Rights Reserved.